[go: up one dir, main page]

WO2019046465A3 - Indoles thérapeutiques - Google Patents

Indoles thérapeutiques Download PDF

Info

Publication number
WO2019046465A3
WO2019046465A3 PCT/US2018/048607 US2018048607W WO2019046465A3 WO 2019046465 A3 WO2019046465 A3 WO 2019046465A3 US 2018048607 W US2018048607 W US 2018048607W WO 2019046465 A3 WO2019046465 A3 WO 2019046465A3
Authority
WO
WIPO (PCT)
Prior art keywords
indoles
therapeutic
compounds
tuberculosis
salts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2018/048607
Other languages
English (en)
Other versions
WO2019046465A2 (fr
Inventor
Joel S. Freundlich
David Alland
Matthew B. NEIDITCH
Daigo Inoyama
Glenn CAPODAGLI
Pradeep Kumar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rutgers State University of New Jersey
Original Assignee
Rutgers State University of New Jersey
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rutgers State University of New Jersey filed Critical Rutgers State University of New Jersey
Publication of WO2019046465A2 publication Critical patent/WO2019046465A2/fr
Publication of WO2019046465A3 publication Critical patent/WO2019046465A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des composés de formule (I) et leurs sels, R1-R4 ayant l'une quelconque des valeurs définies dans la description. Ces composés sont utiles dans le traitement d'infections bactériennes (par ex., la tuberculose).
PCT/US2018/048607 2017-08-29 2018-08-29 Indoles thérapeutiques Ceased WO2019046465A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762551482P 2017-08-29 2017-08-29
US62/551,482 2017-08-29

Publications (2)

Publication Number Publication Date
WO2019046465A2 WO2019046465A2 (fr) 2019-03-07
WO2019046465A3 true WO2019046465A3 (fr) 2019-04-04

Family

ID=65527861

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/048607 Ceased WO2019046465A2 (fr) 2017-08-29 2018-08-29 Indoles thérapeutiques

Country Status (1)

Country Link
WO (1) WO2019046465A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11186549B2 (en) 2017-08-29 2021-11-30 Rutgers, The State University Of New Jersey Therapeutic indazoles

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006067392A2 (fr) * 2004-12-23 2006-06-29 Astrazeneca Ab Composes
US20080004268A1 (en) * 2004-09-24 2008-01-03 Duy Nguyen Inhibitors of soluble adenylate cyclase
US8772305B2 (en) * 2011-01-28 2014-07-08 Boehringer Ingelheim International Gmbh Substituted pyridinyl-pyrimidines and their use as medicaments
US9718840B2 (en) * 2014-01-14 2017-08-01 Sumitomo Dainippon Pharma Co., Ltd. Condensed 5-oxazolidinone derivative

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080004268A1 (en) * 2004-09-24 2008-01-03 Duy Nguyen Inhibitors of soluble adenylate cyclase
WO2006067392A2 (fr) * 2004-12-23 2006-06-29 Astrazeneca Ab Composes
US8772305B2 (en) * 2011-01-28 2014-07-08 Boehringer Ingelheim International Gmbh Substituted pyridinyl-pyrimidines and their use as medicaments
US9718840B2 (en) * 2014-01-14 2017-08-01 Sumitomo Dainippon Pharma Co., Ltd. Condensed 5-oxazolidinone derivative

Also Published As

Publication number Publication date
WO2019046465A2 (fr) 2019-03-07

Similar Documents

Publication Publication Date Title
WO2016179440A3 (fr) Thérapie antimicrobienne
WO2015003816A3 (fr) Cystobactamides
MX2020005348A (es) Formas cristalinas de la n-(4-(4-(ciclopropilmetil)piperazin-1-car bonil)fenil)quinolin-8-sulfonamida.
EP4292650A3 (fr) Composés hétérocycliques en tant qu'immunomodulateurs
PH12018501920A1 (en) Bromodomain inhibitors
AU2016278853A8 (en) Petrolatum-based compositions comprising cationic biocides
WO2015179559A3 (fr) Composés de pyrazole, procédés de production et utilisation
WO2018208985A3 (fr) Composés antibactériens
WO2018208987A3 (fr) Composés antibactériens
WO2016100578A3 (fr) Polymyxines antimicrobiennes pour le traitement d'infections bactériennes
WO2017083431A3 (fr) Composés à base d'hydroxypyridinone et d'hydroxypyrimidinone pour le traitement d'infections bactériennes
CY1124286T1 (el) Συνθεσεις που περιλαμβανουν βακτηριακα στελεχη
WO2016004513A8 (fr) Composés antibactériens modulateurs de la pyruvate kinase, compositions, utilisations et procédés associés
MX2020006191A (es) Bacteriocinas terapeuticas.
EA201992370A1 (ru) Соединения и способы для лечения бактериальных инфекций
EP4327876A3 (fr) Compositions immunogènes
WO2017027359A8 (fr) Pyridines et leur utilisation dans le traitement du cancer
JOP20190129B1 (ar) تركيبات وطرق تتعلق بمواد مساعدة لـ 5-ht1f من بيريدينويل بيبريدين
EP4427815A3 (fr) Pirfénidone enrichie en deutérium et ses procédés d'utilisation
TN2021000092A1 (en) Antibiotic compounds, methods of manufacturing the same, pharmaceutical compositions containing the same and uses thereof
WO2016094374A8 (fr) Compositions et méthodes de traitement de l'ataxie de friedreich
NZ756915A (en) Dual magl and faah inhibitors
PH12019502277A1 (en) Crystalline forms of (s)-afoxolaner
MX2019004375A (es) Inhibidores de bromodominios.
WO2017158616A8 (fr) Composés de carbapénème

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18852531

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18852531

Country of ref document: EP

Kind code of ref document: A2